Article

Clinical Trial: Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

This clinical trial will determine if ketotifen/naphazoline is an effective treatment for acute allergic conjunctivitis.

Click here to access this third party resource:

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

Study Type: Interventional

Age/Gender Requirements: 6 years+ (male/female)

Sponsor: Bausch & Lomb, Inc.

Purpose: To determine the safety and efficacy of ketotifen/naphazoline ophthalmic solution “compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.”

Related Videos
Jörn Schattenberg, MD | Credit: Novo Nordisk
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
Insights from Long-Term ASSURE Data for Seladelpar
What Sets Seladelpar Apart From Other PBC Therapies
The Clinical Impact of Seladelpar in PBC Care
Understanding Seladelpar as a Second-Line Treatment for PBC
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.